NAVAMEDIC ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.1 NOK | -0.90% |
|
+1.53% | -9.81% |
| 05-06 | Navamedic Rolls Out Erectile Dysfunction Drug in Sweden | MT |
| 04-30 | Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 292.1 | 555.8 | 601.2 | 636.8 | 577 | - | - |
| Enterprise Value (EV) 1 | 292.1 | 542.1 | 597.9 | 745.4 | 555.3 | 475.8 | 541 |
| P/E ratio | - | 850 x | 20.2 x | 195 x | 24.2 x | 9.81 x | 8.42 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.39 x | 2 x | 1.57 x | 1.24 x | 0.97 x | 0.84 x | 0.73 x |
| EV / Revenue | 1.39 x | 1.95 x | 1.56 x | 1.46 x | 0.94 x | 0.69 x | 0.68 x |
| EV / EBITDA | - | 29.8 x | 11.6 x | 14.5 x | 9.41 x | 4.89 x | 4.87 x |
| EV / FCF | - | -267 x | 38.1 x | -7.28 x | 46.3 x | 18.3 x | 12 x |
| FCF Yield | - | -0.37% | 2.62% | -13.7% | 2.16% | 5.46% | 8.32% |
| Price to Book | - | - | 2.87 x | - | 1.91 x | 1.52 x | - |
| Nbr of stocks (in thousands) | 15,292 | 16,346 | 17,228 | 17,353 | 17,433 | - | - |
| Reference price 2 | 19.10 | 34.00 | 34.90 | 36.70 | 33.10 | 33.10 | 33.10 |
| Announcement Date | 30/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 209.9 | 278.4 | 382.1 | 512 | 592 | 690.4 | 791 |
| EBITDA 1 | - | 18.2 | 51.69 | 51.57 | 59 | 97.26 | 111 |
| EBIT 1 | - | 11.46 | 44.44 | 39.64 | 47 | 86.34 | 101 |
| Operating Margin | - | 4.11% | 11.63% | 7.74% | 7.94% | 12.51% | 12.77% |
| Earnings before Tax (EBT) 1 | - | 2.358 | 42.51 | 10.83 | 32 | 78.72 | 87 |
| Net income 1 | - | 0.618 | 29.43 | 3.814 | 24 | 61.52 | 68 |
| Net margin | - | 0.22% | 7.7% | 0.74% | 4.05% | 8.91% | 8.6% |
| EPS 2 | - | 0.0400 | 1.730 | 0.1880 | 1.370 | 3.375 | 3.930 |
| Free Cash Flow 1 | - | -2.028 | 15.69 | -102.4 | 12 | 26 | 45 |
| FCF margin | - | -0.73% | 4.11% | -20% | 2.03% | 3.77% | 5.69% |
| FCF Conversion (EBITDA) | - | - | 30.36% | - | 20.34% | 26.73% | 40.54% |
| FCF Conversion (Net income) | - | - | 53.31% | - | 50% | 42.26% | 66.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 30/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.2 | - | 110.4 | 92.81 | 116 | 121.8 | 124 | 141 | 125.3 | 120.9 | 140 | 154 |
| EBITDA 1 | 7.6 | -0.4 | 23.71 | 12.67 | 15.72 | 15.82 | 10.5 | 17.4 | 7.912 | 8.459 | 14 | 16 |
| EBIT 1 | 5.053 | - | 21.88 | 10.89 | 13.92 | 13.99 | 8.297 | 12.7 | 3.521 | 4.897 | 11 | 14 |
| Operating Margin | 5.6% | - | 19.82% | 11.74% | 12% | 11.49% | 6.69% | 9.01% | 2.81% | 4.05% | 7.86% | 9.09% |
| Earnings before Tax (EBT) 1 | 1.979 | - | 9.575 | 5.244 | 27.16 | - | -17.08 | 10.22 | 0.119 | -0.802 | 8 | 10 |
| Net income 1 | 3.025 | - | 7.289 | 2.665 | 20.19 | 13.2 | -15.77 | 6.772 | -0.351 | -1.582 | 6 | 8 |
| Net margin | 3.35% | - | 6.6% | 2.87% | 17.41% | 10.84% | -12.72% | 4.8% | -0.28% | -1.31% | 4.29% | 5.19% |
| EPS | 0.1900 | - | 0.4300 | - | - | - | -0.9200 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/02/22 | 12/05/22 | 12/08/22 | 01/11/22 | 16/02/23 | 11/05/23 | 11/08/23 | 01/11/23 | 15/02/24 | 30/04/24 | - | - |
1NOK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 109 | - | - | - |
| Net Cash position 1 | - | 13.6 | 3.3 | - | 21.7 | 101 | 36 |
| Leverage (Debt/EBITDA) | - | - | - | 2.104 x | - | - | - |
| Free Cash Flow 1 | - | -2.03 | 15.7 | -102 | 12 | 26 | 45 |
| ROE (net income / shareholders' equity) | - | 0.44% | 12.7% | 4.38% | 10% | 20% | 20% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 12.20 | - | 17.30 | 21.70 | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 0.73 | 2.25 | 2.2 | 8 | 11 | 11 |
| Capex / Sales | - | 0.26% | 0.59% | 0.43% | 1.35% | 1.59% | 1.39% |
| Announcement Date | 30/04/21 | 17/02/22 | 16/02/23 | 15/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
33.1
NOK
Average target price
49
NOK
Spread / Average Target
+48.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.81% | 53.2M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- NAVA Stock
- Financials Navamedic ASA
